Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications
- Autores
- Cardinali, Daniel Pedro; Cano Barquilla, Pilar; Jiménez Ortega, Vanesa; Esquifino, Ana I.
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión enviada
- Descripción
- Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Fil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina
Fil: Cano Barquilla, Pilar. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Fil: Jiménez Ortega, Vanesa. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Fil: Esquifino, Ana I. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España
Abstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep‐wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequela in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbilities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease merits further investigation. - Fuente
- Neuroendocrinology 2011, 93 (3)
- Materia
-
MELATONINA
RITMO CIRCADIANO
SINDROME METABOLICO
AGONISTAS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Pontificia Universidad Católica Argentina
- OAI Identificador
- oai:ucacris:123456789/1619
Ver los metadatos del registro completo
id |
RIUCA_f3e493fcb4d8d80781f2e100a6e89c8d |
---|---|
oai_identifier_str |
oai:ucacris:123456789/1619 |
network_acronym_str |
RIUCA |
repository_id_str |
2585 |
network_name_str |
Repositorio Institucional (UCA) |
spelling |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implicationsCardinali, Daniel PedroCano Barquilla, PilarJiménez Ortega, VanesaEsquifino, Ana I.MELATONINARITMO CIRCADIANOSINDROME METABOLICOAGONISTASFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaFil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; ArgentinaFil: Cano Barquilla, Pilar. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; EspañaFil: Jiménez Ortega, Vanesa. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; EspañaFil: Esquifino, Ana I. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; EspañaAbstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep‐wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequela in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbilities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease merits further investigation.Karger Publishers2011info:eu-repo/semantics/articleinfo:eu-repo/semantics/submittedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/16190028-3835 (Print)1423-0194 (Online)10.1159/000324699Cardinali, D. P., et al. Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications [en línea]. Preprint de artículo publicado en Neuroendocrinology. 2011, 93 (3). doi:10.1159/000324699. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1619Neuroendocrinology 2011, 93 (3)reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:19Zoai:ucacris:123456789/1619instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:19.987Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse |
dc.title.none.fl_str_mv |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications |
title |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications |
spellingShingle |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications Cardinali, Daniel Pedro MELATONINA RITMO CIRCADIANO SINDROME METABOLICO AGONISTAS |
title_short |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications |
title_full |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications |
title_fullStr |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications |
title_full_unstemmed |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications |
title_sort |
Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications |
dc.creator.none.fl_str_mv |
Cardinali, Daniel Pedro Cano Barquilla, Pilar Jiménez Ortega, Vanesa Esquifino, Ana I. |
author |
Cardinali, Daniel Pedro |
author_facet |
Cardinali, Daniel Pedro Cano Barquilla, Pilar Jiménez Ortega, Vanesa Esquifino, Ana I. |
author_role |
author |
author2 |
Cano Barquilla, Pilar Jiménez Ortega, Vanesa Esquifino, Ana I. |
author2_role |
author author author |
dc.subject.none.fl_str_mv |
MELATONINA RITMO CIRCADIANO SINDROME METABOLICO AGONISTAS |
topic |
MELATONINA RITMO CIRCADIANO SINDROME METABOLICO AGONISTAS |
dc.description.none.fl_txt_mv |
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina Fil: Cardinali, Daniel Pedro. Universidad de Buenos Aires. Facultad de Medicina. Departamento de Fisiología; Argentina Fil: Cano Barquilla, Pilar. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España Fil: Jiménez Ortega, Vanesa. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España Fil: Esquifino, Ana I. Universidad Complutense. Facultad de Medicina. Departamento de Bioquímica y Biología Molecular III; España Abstract: Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep‐wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequela in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbilities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease merits further investigation. |
description |
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/submittedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
submittedVersion |
dc.identifier.none.fl_str_mv |
https://repositorio.uca.edu.ar/handle/123456789/1619 0028-3835 (Print) 1423-0194 (Online) 10.1159/000324699 Cardinali, D. P., et al. Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications [en línea]. Preprint de artículo publicado en Neuroendocrinology. 2011, 93 (3). doi:10.1159/000324699. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1619 |
url |
https://repositorio.uca.edu.ar/handle/123456789/1619 |
identifier_str_mv |
0028-3835 (Print) 1423-0194 (Online) 10.1159/000324699 Cardinali, D. P., et al. Melatonin and the metabolic syndrome : physiopathologic and therapeutical implications [en línea]. Preprint de artículo publicado en Neuroendocrinology. 2011, 93 (3). doi:10.1159/000324699. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1619 |
dc.language.none.fl_str_mv |
eng eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/4.0/ |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Karger Publishers |
publisher.none.fl_str_mv |
Karger Publishers |
dc.source.none.fl_str_mv |
Neuroendocrinology 2011, 93 (3) reponame:Repositorio Institucional (UCA) instname:Pontificia Universidad Católica Argentina |
reponame_str |
Repositorio Institucional (UCA) |
collection |
Repositorio Institucional (UCA) |
instname_str |
Pontificia Universidad Católica Argentina |
repository.name.fl_str_mv |
Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina |
repository.mail.fl_str_mv |
claudia_fernandez@uca.edu.ar |
_version_ |
1836638330553368576 |
score |
13.13397 |